Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas Leth Frandsen; Jonas Abrahamsson; Birgitte Frederiksen Lausen; Kim Vettenranta; Mats Heyman; Michael Behrentz; Anders Castor; Peder Skov Wehner; Britt-marie Frost; Elisabeth Anne Wreford Andersen; Kjeld Schmiegelow

doi:10.1111/j.1365-2141.2011.08835.x

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas Leth Frandsen, Jonas Abrahamsson, Birgitte Frederiksen Lausen, Kim Vettenranta, Mats Heyman, Michael Behrentz, Anders Castor, Peder Skov Wehner, Britt-marie Frost, Elisabeth Anne Wreford Andersen, Kjeld Schmiegelow

9 Citations (Scopus)

Abstract

This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

Original language	English
Journal	British Journal of Haematology
Volume	155
Issue number	2
Pages (from-to)	244-247
Number of pages	4
ISSN	0007-1048
DOIs	https://doi.org/10.1111/j.1365-2141.2011.08835.x
Publication status	Published - Oct 2011

Access to Document

10.1111/j.1365-2141.2011.08835.x

Fingerprint

Dive into the research topics of 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study'. Together they form a unique fingerprint.

Cite this

Frandsen, T. L., Abrahamsson, J., Lausen, B. F., Vettenranta, K., Heyman, M., Behrentz, M., Castor, A., Wehner, P. S., Frost, B., Andersen, E. A. W., & Schmiegelow, K. (2011). Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology, 155(2), 244-247. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. / Frandsen, Thomas Leth; Abrahamsson, Jonas; Lausen, Birgitte Frederiksen et al.
In: British Journal of Haematology, Vol. 155, No. 2, 10.2011, p. 244-247.

Research output: Contribution to journal › Journal article › Research › peer-review

Frandsen, TL, Abrahamsson, J, Lausen, BF, Vettenranta, K, Heyman, M, Behrentz, M, Castor, A, Wehner, PS, Frost, B, Andersen, EAW & Schmiegelow, K 2011, 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study', British Journal of Haematology, vol. 155, no. 2, pp. 244-247. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Frandsen TL, Abrahamsson J, Lausen BF, Vettenranta K, Heyman M, Behrentz M et al. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology. 2011 Oct;155(2):244-247. doi: 10.1111/j.1365-2141.2011.08835.x

Frandsen, Thomas Leth ; Abrahamsson, Jonas ; Lausen, Birgitte Frederiksen et al. / Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia : A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. In: British Journal of Haematology. 2011 ; Vol. 155, No. 2. pp. 244-247.

@article{0debd21f793143c3841c3d163ca0b1ae,

title = "Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study",

abstract = "This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity. ",

author = "Frandsen, {Thomas Leth} and Jonas Abrahamsson and Lausen, {Birgitte Frederiksen} and Kim Vettenranta and Mats Heyman and Michael Behrentz and Anders Castor and Wehner, {Peder Skov} and Britt-marie Frost and Andersen, {Elisabeth Anne Wreford} and Kjeld Schmiegelow",

year = "2011",

month = oct,

doi = "10.1111/j.1365-2141.2011.08835.x",

language = "English",

volume = "155",

pages = "244--247",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia

T2 - A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

AU - Frandsen, Thomas Leth

AU - Abrahamsson, Jonas

AU - Lausen, Birgitte Frederiksen

AU - Vettenranta, Kim

AU - Heyman, Mats

AU - Behrentz, Michael

AU - Castor, Anders

AU - Wehner, Peder Skov

AU - Frost, Britt-marie

AU - Andersen, Elisabeth Anne Wreford

AU - Schmiegelow, Kjeld

PY - 2011/10

Y1 - 2011/10

N2 - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

AB - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

U2 - 10.1111/j.1365-2141.2011.08835.x

DO - 10.1111/j.1365-2141.2011.08835.x

M3 - Journal article

C2 - 21848519

SN - 0007-1048

VL - 155

SP - 244

EP - 247

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -